Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Cetuximab binds to the extracellular domain of EGFR and blocks ligand binding, leading to receptor inactivation, internalization and degradation. Cetuximab is approved for combination therapy and monotherapy of metastatic colorectal cancer and advanced squamous cell carcinoma of head and neck in patients whose tumors over-express wild-type EGFR protein, usually due to amplification of EGFR gene.
Literature References
PubMed ID Title Journal Year
15269313 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Bleiberg, H, Humblet, Y, Mueser, M, Khayat, D, Chau, I, Cunningham, D, Bets, D, Verslype, C, Santoro, A, Harstrick, A, Siena, S, Van Cutsem, E

N Engl J Med 2004
15837620 Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

Ferguson, KM, Wiltzius, JJW, Schmitz, KR, Li, S, Kussie, P, Jeffrey, PD

Cancer Cell 2005
16314626 Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

Forastiere, AA, Burtness, B, Eastern Cooperative Oncology, Group, Flood, W, Goldwasser, MA, Mattar, B

J Clin Oncol 2005
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
head and neck squamous cell carcinoma DOID:5520 carcinoma of the head and neck, squamous cell carcinoma of the head and neck
large intestine cancer DOID:5672 malignant Colorectal tumor, malignant neoplasm of large intestine, NOS, malignant tumor of large intestine (disorder), malignant neoplasm of colon with rectum, malignant neoplasm of large intestine NOS
Cite Us!